Page 5 - David Traylor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Look, sometimes things can just go wrong. But often it's the way people RESPOND in these situations that reveals the excellence of the staff. Kudos.

Look, sometimes things can just go wrong. But often it's the way people RESPOND in these situations that reveals the excellence of the staff. Kudos.

The ongoing pandemic has created a wealth of interest from venture capital investors and the broader public in what biotech companies are able to achieve if it’s flush with resources. That was the sentiment of a group of Boulder area biotechnology industry leaders, who met virtually at BizWest’s CEO Roundtable on the biotechnology industry Tuesday morning. Steady stream of investor dollars Biotech was one of the few industries that was relatively unaffected from a financial standpoint during the pandemic, and multiple companies marked significant financial milestones just in the past few ...

This month, two groundbreaking deals in cannabis were announced — the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator (MSO) Parallel with the special purpose acquisition company (SPAC), Ceres Acquisition Corp. The proximity of two such large deals in one month begs the question:  Are the GW Pharma — Jazz and Ceres — Parallel deals an important barometer to the direction of cannabis, both in North America and abroad?  In His Genes The biopharma influence on the cannabis sector started early with the drive toward adoption of curr...

Activity is heating up in the U.S. as the number of states that have legalized marijuana is increasing. With the cannabis market growing stronger than ever and many big players entering the field, an increase in the value of mergers and acquisitions (M&A) have taken place. Recently, Canada's Tilray (NASDAQ: TLRY) and Aphria (NASDAQ: APHA) announced a near $4 billion merger. If that wasn't impressive enough, Jazz Pharmaceuticals' (NASDAQ: JAZZ) $7.2 billion purchase of GW Pharmaceuticals (NASDAQ: GWPH) earlier in February makes it the biggest tie-up yet for the cannabis industry. This means so...